Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma

F. Cavalli, A. Goldhirsch, P. Siegenthaler, S. Kaplan, M. Beer

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-four patients with small cell cancer of the lung were treated with cisplatin. The drug was given at a dose of 80 mg/m2 in a 6-hr infusion repeated every 3 weeks. All but 1 patient had received extensive prior therapy. Of 23 patients evaluable for response, 5 achieved partial remission. A minor response was noted in 3 additional patients. Nausea and vomiting were prominent. Mild to moderate myelosuppression and nephrotoxicity were commonly encountered. There was one, probably drug-related, death with renal impairment after apparently optimal forced diuresis. These data warrant the incorporation of cisplatin in combination chemotherapy for this disease.

Original languageEnglish
Pages (from-to)617-621
Number of pages5
JournalEuropean Journal of Cancer (1965)
Volume16
Issue number5
DOIs
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma'. Together they form a unique fingerprint.

Cite this